IP Library › Granted Patent US 12,503,499
Granted Patent B2
US 12,503,499 · App. 17/470,463 · Granted Dec 23, 2025

Modified HIV-1 proviral vectors with enhanced dendritic cell transduction efficiencies comprising the JRFL envelope

Inventor: Jeremy Luban (Newton, MA)
Assignee: UNIVERSITY OF MASSACHUSETTS
C07K16/1063A61K39/12A61K39/21C07K16/1045C07K16/1207C12N15/86A61K31/7088A61K39/0225C07K2317/14C07K2317/76C12N2740/10044C12N2740/16021C12N2740/16023C12N2740/16034C12N2740/16043C12N2740/16044C12N2740/16122C12N2740/16134C12N2740/16322
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,503,499
App. No.
17/470,463
Granted
Dec 23, 2025
Kind
B2
Abstract

The present invention provides highly efficient methods, and compositions related thereto, for generating high titer human antibodies or antibody fragments thereof in a mammalian subject. The methods comprise administering a virus or virus-like particle to a mammal comprising heterologous immune cells and isolating a population of immunoglobulin-producing cells from the mammal, thereby producing the antibodies or antibody fragments thereof.

Claims (13)

1 . An isolated nucleotide sequence having at least about 95% identity over the entire length of its coding sequence compared to the coding sequence of SEQ ID NO: 7, 8, or 9, wherein an amino acid sequence encoded by the coding sequence of the isolated nucleotide sequence is identical to an amino acid sequence encoded by the coding sequence of SEQ ID NO: 7, 8, or 9, respectively.

2 . The isolated nucleotide sequence of claim 1 , having at least about 96% identity over the entire length of its coding sequence to the coding sequence of SEQ ID NO:7.

3 . The isolated nucleotide sequence of claim 1 , having at least about 97% identity over the entire length of its coding sequence to the coding sequence of SEQ ID NO:7.

4 . The isolated nucleotide sequence of claim 1 , having at least about 98% identity over the entire length of its coding sequence, having a nucleotide sequence of SEQ ID NO:7.

5 . The isolated nucleotide sequence of claim 1 , having at least about 99% identity over the entire length of its coding sequence to the coding sequence of SEQ ID NO:7.

6 . The isolated nucleotide sequence of claim 1 , having at least about 96% identity over the entire length of its coding sequence to the coding sequence of SEQ ID NO: 8.

7 . The isolated nucleotide sequence of claim 1 , having at least about 97% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO: 8.

8 . The isolated nucleotide sequence of claim 1 , having at least about 98% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO: 8.

9 . The isolated nucleotide sequence of claim 1 , having at least about 99% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO: 8.

10 . The isolated nucleotide sequence of claim 1 , having at least about 96% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO:9.

11 . The isolated nucleotide sequence of claim 1 , having at least about 97% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO:9.

12 . The isolated nucleotide sequence of claim 1 , having at least about 98% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO:9.

13 . The isolated nucleotide sequence of claim 1 , having at least about 99% identity over the entire length of the sequence of its coding sequence to the coding sequence of SEQ ID NO:9.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2025
From: LUBAN, JEREMY
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 073013/0452 →
Continuity (3)
Division 16073472
Provisional Application 62305891 · Mar 9, 2016
Related Publication 20220106385A1 · Apr 7, 2022
References Cited (54)
US 5512421A · Burns et al. · 1996 [cited by applicant]
US 5739018A · Miyanohara et al. · 1998 [cited by applicant]
US 5814500A · Dietz · 1998 [cited by applicant]
US 5885806A · Dropulic et al. · 1999 [cited by applicant]
US 8071284B2 · Gupta · 2011 [cited by examiner]
US 11142566B2 · Luban · 2021 [cited by applicant]
US 20110263460A1 · Quinones-Mateu et al. · 2011 [cited by applicant]
US 20140329312A1 · North et al. · 2014 [cited by applicant]
CN 1489630A · 2004 [cited by applicant]
CN 105263506A · 2016 [cited by applicant]
EP 3426353A1 · 2019 [cited by applicant]
WO WO2001047955A2 · 2001 [cited by applicant]
WO WO2004037699A2 · 2004 [cited by applicant]
WO WO2017156170A1 · 2017 [cited by applicant]
Von Schwedler, U. K., et al., May 2003, Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein, J. Virol. 77(9):5439-5450. [cited by examiner]
Melamed, D., et al., Sep. 2004, The Conserved Carboxy Terminus of teh Capsid Domain of Human Immunodeficiency Virus Type 1 Gag Protein is Important for Virion Assembly and Release, J. Virol. 78(18):9675-9688. [cited by examiner]
Adachi, et al., Production of Acquired Immunodeficiency Syndrome-Associated Retrovirus in Human and Nonhuman Cells Transfected With an Infectious Molecular Clone, Journal of Virology, vol. 59, No. 2, pp. 284-291, 1986. [cited by applicant]
Akkina, Ramesh, Humanized Mice for Studying Human Immune Responses and Generating Human Monoclonal Antibodies, Microbial. Spectrum, vol. 2, No. 2, AID-0003-2012, pp. 1-12, 2014. [cited by applicant]
Andre, et al., Increased Immune Response Elicited by DNA Vaccination With a Synthetic Gp120 Sequence With Optimized Codon Usage, Journal of Virology, vol. 72, No. 2, pp. 1497-1503, 1998. [cited by applicant]
Baker, et al., Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction, Biophysical Journal, vol. 60, No. 6, pp. 1445-1456, 1991. [cited by applicant]
Brainard, et al., Induction of Robust Cellular and Humoral Virus-Specific Adaptive Immune Responses in Human Immunodeficiency Virus-Infected Humanized BLT Mice, Journal of Virology, vol. 83, No. 14, pp. 7305-7321, Jul. … [cited by applicant]
Crooks, et al., Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD˜ Binding Site, PLoS Pathogens, vol. 11, No. 5, pp. 1-34, May 29, 20… [cited by applicant]
Database Genseq, HIV-1 B Envelope Polypeptide Encoding cDNA, Retrieved from EBI accession No. BBC45288, Apr. 10, 2014. [cited by applicant]
EMBL Database, HIV-1 Isolate JRCSF clone from USA Envelope Glycoprotein (env) Gene, Partial CDS, Retrieved from EBI Accession No. EM STD: AY669726, Aug. 2004. [cited by applicant]
Extended European Search Report for European Application No. 17764030.7, mailed Apr. 3, 2020. [cited by applicant]
Fikrig, et al., Protection of Mice Against the Lyme Disease Agent by Immunizing with Recombinant OspA, Science, vol. 250, No. 4980, pp. 553-556, Oct. 1, 1990. [cited by applicant]
Genbank, HIV-1 Isolate JRCSF From USA Envelope Glycoprotein (Env) Gene, Complete CDS, “Accession No. AY426125.1, Retrieved from: https://www.ncbi.nlm.nih.gov/nuccore/AY426125”, Jun. 1, 2004. [cited by applicant]
Gish, et al., Identification of Protein Coding Regions by Database Similarity Search, Nature Genetics, vol. 3, No. 3, pp. 266, 1993. [cited by applicant]
Gorman, et al., Reshaping a Therapeutic CD4 Antibody, Proceedings of the National Academy of Sciences, vol. 88, No. 10, pp. 4181-4185, 1991. [cited by applicant]
Granelli-Piperno, Dendritic Cells, Infected With Vesicular Stomatitis Virus-Pseudotyped HIV-1, Present Viral Antigens to CD4+ and CD8+ T Cells From HIV-1-Infected Individuals, the Journal of Immunology, vol. 165, No. 11… [cited by applicant]
Hagensee, et al., Three-Dimensional Structure of Vaccinia Virus-Produced Human Papillomavirus Type 1 Capsids, Journal of Virology, vol. 68, No. 7, pp. 4503-4505, 1994. [cited by applicant]
Hodgson, John, Making Monoclonals in Microbes, Biotechnology, vol. 9, pp. 421-425, 1991. [cited by applicant]
International Search Report and Written Opinion for PCT Patent Application No. PCT/US2017/21426, mailed Jul. 7, 2017. [cited by applicant]
Jones, et al., Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse, Nature, vol. 321, No. 6069, pp. 522-525, May 29, 1986. [cited by applicant]
Karlin, et al., Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences, Proceedings of the National Academy of Sciences of the USA, vol. 90, pp. 5873-5877, Jun. 1, 1993. [cited by applicant]
Karlin, et al., Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes, Proceedings of the National Academy of science of the USA, vol. 87, No. 6, pp. 2264-226… [cited by applicant]
Koyanagi, et al., Dual Infection of the Central Nervous System by AIDS Viruses With Distinct Cellular Tropisms, Science, vol. 236, No. 4803, pp. 819-822, 1987. [cited by applicant]
Kramer, et al., The Human Antibody Repertoire Specific for Rabies Virus Glycoprotein as Selected From Immune Libraries, European Journal of Immunology, vol. 35, No. 7, pp. 2131-2145, 2005. [cited by applicant]
Lan, et al., Reconstitution of a Functional Human Immune System in Immunodeficient Mice Through Combined Human Fetal Thymus/Liver and CD34+ Cell Transplantation, Blood, vol. 108, No. 2, pp. 487-492, 2006. [cited by applicant]
Liu, et al., Chimeric Mouse-Human IgG1 Antibody That Can Mediate Lysis of Cancer Cells, Proceedings of the National Academy of Sciences, vol. 84, No. 10, pp. 3439-3443, 1987. [cited by applicant]
Marsden, et al., Humanized Mouse Models for Human Immunodeficiency Virus Infection, Annual Review of Virology, vol. 4, pp. 393-412, Sep. 1, 2017. [cited by applicant]
Melkus, et al., Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1, Nature medicine, vol. 12, No. 11, pp. 1316-1322, 2006. [cited by applicant]
Neagu, et al., Potent Inhibition of HIV-1 by TRIM5-Cyclophilin Fusion Proteins Engineered From Human Components, the Journal of Clinical Investigation, vol. 119, No. 10, pp. 3035-3047, 2009. [cited by applicant]
Peters, et al., Biological Analysis of Human Immunodeficiency Virus Type 1 R5 Envelopes Amplified from Brain and Lymph Node Tissues of AIDS Patients with Neuropathology Reveals Two Distinct Tropism Phenotypes and Identi… [cited by applicant]
Queen, C., et al., A humanized antibody that binds to the interleukin 2 receptor, Proceeding of National Academy of Science, USA. vol. 86, No. 24, pp. 10029-10033, Dec. 1, 1989. [cited by applicant]
Reiser, et al., Development of Multigene and Regulated Lentivirus Vectors, Journal of virology, vol. 74, No. 22, pp. 10589-10599, 2000. [cited by applicant]
Sato, et al., Dynamics of Memory and Naive CDS+ T Lymphocytes in Humanized NOD/SCID/IL-2Rγnull Mice Infected with CCR5-tropic HIV-1, Vaccine, vol. 28, pp. B32-B37, 2010. [cited by applicant]
Shultz, et al., Generation of Functional Human T-Cell Subsets With HLA-Restricted Immune Responses in HLA Class I Expressing Nod/Scid/II2rγnull Humanized Mice, Proceedings of the National Academy of Sciences, vol. 107, … [cited by applicant]
Shultz, et al., Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted With Mobilized Human Hemopoietic Stem Cells, the Journal of Immunology, vol. 174, No. 10, pp. 6477-6489, 2005. [cited by applicant]
Shultz, et al., Humanized Mice from Immune System Investigation: Progress, Promise, and Challenges, Nature Reviews Immunology, vol. 12, No. 11, pp. 786-798, Nov. 1, 2012. [cited by applicant]
Tonomura, et al., Antigen-Specific Human T-Cell Responses and T Cell-Dependent Production of Human Antibodies in a Humanized Mouse Model, Blood, vol. 111, No. 8, pp. 4293-4296, 2008. [cited by applicant]
Verhoeyen, et al., Reshaping Human Antibodies: Grafting an Antilysozyme Activity, Science, vol. 239, No. 4847, pp. 1534-1536, Mar. 25, 1988. [cited by applicant]
U.S. Appl. No. 16/073,472 2019/0062409 U.S. Pat. No. 11,142,566, filed Jul. 27, 2018 Feb. 28, 2019 Oct. 12, 2021, Jeremy Luban. [cited by applicant]
U.S. Appl. No. 17/470,463 2022/0106385, filed Sep. 9, 2021 Apr. 7, 2022, Jeremy Luban. [cited by applicant]